Keenova Therapeutics to sell Percocet and Endocet businesses to Par Health for up to $250M

Keenova Therapeutics plc

Upfront purchase price $25M; quarterly earnout payments over 5 years based on gross profit of the Business.
Transaction expected to close in Q3 2026, subject to HSR clearance and other customary closing conditions.
After closing, Keenova will no longer market, manufacture, or distribute opioid products.
Consideration total up to ~$250M; deal includes Percocet and Endocet businesses sold to Par Health, Inc.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.